Tezspire 210 mg Patient Leaflet: Key Information
Quick summary Tezspire (tezepelumab) is a treatment used for certain people with severe asthma and chronic rhinosinusitis with nasal polyps. It is given as a subcutaneous injection and is not a rescue medicine for...
This content is for educational purposes only and does not replace medical advice, diagnosis or treatment from a qualified healthcare professional.
Quick summary
Tezspire (tezepelumab) is a treatment used for certain people with severe asthma and chronic rhinosinusitis with nasal polyps. It is given as a subcutaneous injection and is not a rescue medicine for sudden asthma symptoms.
Medical disclaimer
This article is a general summary of the patient leaflet and does not replace the official leaflet or advice from a doctor, nurse, or pharmacist. Always follow the instructions given with your prescribed medicine.
What is Tezspire and what is it used for?
Tezspire contains tezepelumab. It is described in the leaflet as a medicine used to help manage severe asthma and chronic rhinosinusitis with nasal polyps in patients over 12 years old.
It is used as an additional treatment alongside other therapies. It is not intended to treat a sudden asthma attack.
How Tezspire works
Tezspire works by targeting the TSLP protein, which is involved in inflammation in the airways. By blocking this protein, it helps reduce inflammation and support better breathing control.
This mechanism is one reason it may be used in people whose symptoms have not been adequately controlled with existing treatment.
How Tezspire is given
Tezspire is given as a subcutaneous injection, meaning it is injected under the skin.
The leaflet states the usual dose as 210 mg every four weeks. A healthcare professional may show the patient or caregiver how the injection is given.
Rotating injection sites may help reduce local discomfort. If there is any uncertainty about the injection process, the official leaflet and healthcare team should be consulted.
Dosage information at a glance
| Item | Information in the leaflet |
|---|---|
| Strength | 210 mg |
| How it is given | Subcutaneous injection |
| Usual schedule | Every 4 weeks |
| Use | Additional treatment for certain patients with severe asthma or chronic rhinosinusitis with nasal polyps |
Possible side effects
As with any medicine, Tezspire may cause side effects, although not everyone gets them. The current content mentions the following possible effects:
- Pain or discomfort at the injection site
- Respiratory infections
- Headache
- Fatigue
- Flu-like symptoms
Allergic reactions are also important to watch for. The leaflet summary mentions rash, itching, or swelling as possible warning signs that should be discussed with a healthcare professional.
Precautions and important safety points
Before using Tezspire, the patient should discuss their medical history with a healthcare professional. The current content highlights the following points to check:
- Any previous allergic reaction to tezepelumab or similar medicines
- Other medicines being used, including corticosteroids
- Whether live vaccines are planned or being given
The content also notes that corticosteroids should not be reduced suddenly without medical guidance.
Who may not be suitable for Tezspire?
Tezspire is not suitable for everyone. The content states that it should not be used in people with a known hypersensitivity to tezepelumab or any of its components.
Questions about suitability should be reviewed with a doctor or pharmacist using the official leaflet and the patient’s own medical history.
What to discuss with a doctor or pharmacist
Before treatment, it is sensible to confirm:
- Why Tezspire has been prescribed
- How and when the injection should be given
- What to do if a dose is missed
- Which side effects should be reported promptly
- Whether any vaccines or other medicines need review
This helps the patient use the medicine in line with the prescribed plan and the official leaflet.
Frequently asked questions
▸ What is Tezspire?
Tezspire is a medicine containing tezepelumab. It is used for certain patients over 12 years old with severe asthma or chronic rhinosinusitis with nasal polyps.
▸ How is Tezspire given?
It is given as a subcutaneous injection. The leaflet states a usual schedule of 210 mg every four weeks.
▸ Is Tezspire a rescue medicine for asthma attacks?
No. The content states that Tezspire is not a rescue medicine for sudden asthma symptoms or acute attacks.
▸ What side effects are mentioned in the leaflet summary?
The content mentions injection-site discomfort, respiratory infections, headache, fatigue, and flu-like symptoms.
▸ What should be checked before starting treatment?
A doctor or pharmacist should review allergies, other medicines, vaccine plans, and the patient’s medical history before treatment is used.
Safety reminder
If symptoms worsen, if there are signs of an allergic reaction, or if there is any uncertainty about how Tezspire should be used, seek advice from a healthcare professional promptly. Always refer to the official patient leaflet for the most complete instructions.
Medical disclaimer
This content is for educational purposes only. It should not be used as a substitute for professional medical advice, diagnosis or treatment. Always ask a doctor, pharmacist or qualified healthcare professional before starting, stopping or changing any medicine.
Sources and verification
The following sources or official references are listed to support verification of the medicine information discussed in this article.
- Tezspire Summary of Product Characteristics (SmPC)
- Tezspire Patient Information Leaflet
- NHS: Asthma treatment overview
- NHS: Nasal polyps
To improve this article with specific references, add a custom field named _aio_sources in the post editor and write one source per line using: Source title|Source URL.
Medicine information can change and may vary depending on country, product formulation, patient history and professional guidance. Always check official medicine information and ask a healthcare professional for personal medical questions.